In Giant Cell Tumor of Bone, Denosumab Shows Robust Clinical Efficacy

Share this content:
Denosumab has robust clinical efficacy in the treatment of patients with giant cell tumor of bone.
Denosumab has robust clinical efficacy in the treatment of patients with giant cell tumor of bone.

Denosumab has robust clinical efficacy in the treatment of patients with giant cell tumor of bone (GCTB), a new study published online ahead of print in the journal Annals of Oncology has shown.

GCTB is a rare primary bone tumor that expresses receptor activator of nuclear factor-kappa B (RANK) and RANK ligand (RANKL). Therefore, researchers sought to evaluate the efficacy of denosumab, a RANKL specific inhibitor in patients with GCTB.

For the phase 2 trial, researchers enrolled 17 patients with GCTB. All patients received denosumab 120 mg every 4 weeks, with a loading dose of 120 mg on days 8 and 15. Patients were treated for a median of 13.1 months.

Results showed that 88% of patients achieved an objective tumor response based on best response using any tumor response criteria. Based on the modified RECIST criteria, 35% of patients achieved an objective tumor response.

RELATED: Survival Rate for Rare Form of Bone Cancer Improving

Researchers found that 82% and 71% had an objective tumor response based on the modified EORTC and Choi criteria, respectively.

Denosumab is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Reference

  1. Ueda T, Morioka H, Nishida Y, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase 2 trial. Ann Oncol. 2015. [epub ahead of print] doi: 10.1093/annonc/mdv307.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters